Core Viewpoint - Anke Biological (300009) is advancing two clinical trials for products targeting respiratory viral infections in children, marking a significant step in addressing urgent healthcare needs in this demographic [1] Group 1: Clinical Trials - Anke Biological held a researcher meeting for the Phase II/III clinical trial of AK1012 inhalation solution and the Phase III clinical trial of human interferon α2b spray [1] - Both products are entering the final stages of clinical verification, focusing on common and urgent diseases affecting children [1] Group 2: Product Details - AK1012 inhalation solution is a modified new formulation of the already marketed product, human interferon α2b injection, intended for treating lower respiratory tract infections caused by respiratory syncytial virus (RSV) in children [1] - The human interferon α2b spray is aimed at treating herpetic pharyngitis in children [1]